Summarized by Masters of Longevity from Longevity Technology.
A biotech–big-pharma collaboration update about the start of large-scale clinical testing for an investigational oral weight and cardiometabolic therapy, with context on program scope and industry implications.
Key Takeaways
- AstraZeneca initiated a global Phase 3 program for an oral small-molecule GLP-1 receptor agonist called elecoglipron.
- Eccogene received a $50 million milestone payment tied to the Phase 3 start.
